StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

Equities research analysts at StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued on Saturday. The firm set a “sell” rating on the stock.

A number of other analysts have also issued reports on the stock. D. Boral Capital reissued a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a research report on Thursday. Benchmark restated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Trading Down 3.2 %

Shares of VNRX stock opened at $0.60 on Friday. The company has a market capitalization of $55.60 million, a price-to-earnings ratio of -1.67 and a beta of 1.20. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.22. The stock’s fifty day simple moving average is $0.62 and its 200-day simple moving average is $0.65.

Insider Activity

In other news, CEO Cameron John Reynolds bought 139,811 shares of the business’s stock in a transaction on Monday, December 9th. The stock was purchased at an average price of $0.57 per share, with a total value of $79,692.27. Following the transaction, the chief executive officer now directly owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. The trade was a 7.07 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Guy Archibald Innes purchased 174,764 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were purchased at an average price of $0.57 per share, with a total value of $99,615.48. Following the completion of the acquisition, the director now directly owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 358,266 shares of company stock worth $204,212. 12.80% of the stock is owned by corporate insiders.

Institutional Trading of VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC boosted its position in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. 8.09% of the stock is owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.